Efficacy of PRRT in Metastatic Neuroendocrine Tumors; A Retrospective Large Single Institutional Study

#1125

Introduction: PRRT is a well-documented and well-established treatment for metastatic neuroendocrine tumours. However retrospective studies detailing the efficacy of PRRT are lacking.

Aim(s): This study aims to retrospectively analyse factors that affect increased survival and improve QOL in patients who receive PRRT.

Materials and methods: The study includes a total of 57 patients who were treated at the Royal Brisbane and Women’s Hospital in the last 5 years with PRRT. Data were collected by studying individual patient records and charts. The factors studied include presence or absence of liver metastases, GE vs. pancreatic histology, Ki 67, number of cycles and dose of PRRT, adverse effects, delays in treatment and improvement of QOL and PFS. In addition OS is being calculated using historical controls.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Jan H

Authors: Jan H, Wyld D, Burge M,

Keywords: lutetium, somatostatin receptor, PRRT, neuroendocrine tumors,